Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly

Vaccine

Volumn 17, Issue 23-24, 1999, Pages 3094-3101

  De Donato, S ^a   Granoff, D ^b   Minutello, M ^b   Lecchi, G ^a   Faccini, M ^a   Agnello, M ^a   Senatore, F ^b   Verweij, P ^c   Fritzell, B ^b   Podda, A ^b  

^a Locale No 31 SS Giovanni   (Italy)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Chiron Biostatist Clin Data Mgmt   (Netherlands)

Author keywords

Adjuvant; Influenza; MF59; Vaccine

Indexed keywords

IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; UNCLASSIFIED DRUG;

AGED; ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GERIATRIC DISORDER; HEADACHE; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INJECTION PAIN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT INDICATION;

ADJUVANTS, IMMUNOLOGIC; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; DOUBLE-BLIND METHOD; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNIZATION SCHEDULE; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA VACCINES; MALE; MIDDLE AGED; POLYSORBATES; SQUALENE; VACCINES, INACTIVATED;

EID: 0033529516     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00138-3     Document Type: Article

References (34)

1. Barker W.H. Excess pneumonia and influenza associated hospitalisation during influenza epidemics in the United States. Am J Pub Health. 76:1986;761-765.
2. Barker W.H., Mullooly J.P. Impact of epidemic type A influenza in a defined adult population. Am J Epidemiol. 112:1980;798-811.
3. Glezen W.P., Six H.R., Frank A.L., Taber L.H., Perrotta D.M., Decker M. Impact of epidemics upon communities and families. Kendal A.P., Patriarca P.A. Options for the Control of Influenza. 1986;63-73 Alan R. Liss, Inc, New York, NY.
4. Sprenger M.J.W., Beyer W.E.P., Kempen B.M., Mulder P.G.H., Masurel N. Risk factors for influenza mortality? Kendal A.P., Klenk H.D., Ruben F.L. Options for the Control of Influenza II. 1993;15-23 Excerpta Medica, New York, NY.
5. Lui K.J., Kendal A.P. Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985. Am J Public Health. 77:1987;712-716.
6. Arden N.H., Patriarca P.A., Kendal A.P. Experiences in the use and efficacy of inactivated influenza vaccine in nursing homes. Kendal A.P., Patriarca P.A. Options for the Control of Influenza. 1986;155-168 Arlan R. Liss, Inc, New York, NY.
7. Barker W.H., Mullooly J.P. Effectiveness of inactivated influenza vaccine among non-institutionalized elderly persons. Kendal A.P., Patriarca P.A. Options for the Control of Influenza. 1986;169-182 Alan R. Liss, Inc, New York, NY.
8. Govaert T.M., Thijs C.T., Masurel N., Sprenger M.J.W., Dinant G.J., Knottnerus J.A. The efficacy of influenza vaccination in elderly individuals. JAMA. 272:1994;1661-1665.
9. Gross P.A., Hermogenes A.W., Sacks H.S., Lau J., Levandowski R.A. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med. 123:1995;518-527.
10. Gross P.A., Quinnan G.V. Jr., Weksler M.E., Setia U., Douglas R.G. Jr. Relation of chronic disease and immune response to influenza vaccine in the elderly. Vaccine. 7:1989;303-308.
11. Strassburg M.A., Greenland S., Sorvillo F.J., Lieb L.E., Habel L.A. Influenza in the elderly: report of an outbreak and review of vaccine effectiveness reports. Vaccine. 4:1986;38-44.
12. Beyer W.E.P., Palache A.M., Baljet M., Masurel N. Antibody induction by influenza vaccines in the elderly: a review of the literature. Vaccine. 7:1989;385-394.
13. Meiklejohn G., Eickhoff T.C., Graves P. Antigenic drift and efficacy of influenza virus vaccines. J Infect Dis. 138:1978;618-624.
14. Monto A.S. Influenza vaccines for the elderly [editorial]. N Engl J Med. 331:1994;807-808.
15. Palache A.M. Dose-comparative serological studies: critical evaluation of the parameters to assess the antibody response to influenza vaccination. Anonymous influenza vaccination. The effect of dose and age on the antibody response. 1991;83-119 Broos Amsterdam BV, Amsterdam, Netherlands.
16. Edelman R. Vaccine adjuvants. Rev Infect Dis. 2:1980;370-383.
17. Ott G., Barchfeld G.L., Chernoff D., Radhakrishnan R., van Hoogevest P., Van Nest G. MF59: Design and evaluation of a safe and potent adjuvant for human vaccines. Powell M.F., Newman M.J. Vaccine design: the subunit and adjuvant approach. 1995;277-295 Plenum Press, New York.
18. 197 conjugate vaccine. Infect Immun. 65:1997;1710-1715.
19. Ott G., Barchfeld G.L., Chernoff D., Radhakrishnan R., van Hoogevest P., Van Nest G. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm. Biotechnol. 6:1995;277-296.
20. Van Nest G.A., Steimer K.S., Haigwood N.L., Burke R.L., O.H G. Advanced adjuvant formulations for use with recombinant subunit vaccines. Brown F., Chanock R.M., Ginsberg H.S., Lerner R.A. Vaccines. vol. 92:1992;57-62 Cold Spring Harbor Laborotory Press, Cold Spring Harbor.
21. Kahn J.O., Sinangil F., Baenziger J., Murcar N., Wynne D., Coleman R.L., et al. Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2. J Infect Dis. 170:1994;1288-1291.
22. Langenberg A.G., Burke R.L., Adair S.F., Sekulovich R., Tigges M., Dekker C.L., et al. A recombinant glycoprotein vaccine for Herpes simplex virus type 2: safety and immunogenicity. Ann Intern Med. 122:1995;889-898.
23. Wara D, Borkowsky W, McNamara J, Mofenson L, Duliege AM, Francis D, et al. Safety of recombinant HIV-1 envelope vaccines in newborns of infected mothers - a phase I study. Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy 1995. p. 231.
24. Mitchell D.K., Holmes S.J., Burke R.L., Sekulovich R., Tripathi M., Doyle M., et al. Immunogenicity of a recombinant human cytomegalovirus (CMV) gB vaccine in toddlers. Program and Abstracts of the 6th International Cytomegalovirus Workshop 1997. 1997;A-25. Abstract.
25. Minutello A., Senatore F., Cecchini D., Bianchi M., Andreani T., Podda A., et al. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine. 17:1999;99-104.
26. World Health Organization. Recommended composition of influenza virus vaccines for use in the 1993-1994 season. Weekly Epidemiol Rec. 68:1993;57.
27. World Health Organization. Recommended composition of influenza virus vaccines for use in the 1994-1995 season. Weekly Epidemiol Rec. 70:1994;53-56.
28. World Health Organization. Recommended composition of influenza virus vaccines for use in the 1995-1996 season. Weekly Epidemiol Rec. 70:1995;53-56.
29. Dowdle W.N., Kendal A.P., Noble G.R. Influenza viruses. Lenette E.H., Schmidt N.J. Diagnostic procedures for viral, ricksettsial and chlamydial infections. 1979;603-605 American Public Health Association, Washington, DC.
30. Frank A.L., Puck J., Hughes B.J., et al. Microneutralization test for influenza A and B and parainfluenza 1 and 2 viruses that uses continuous cell lines and fresh serum enhancement. J Clin Microbiol. 12:1980;426-432.
31. Masurel N., Laufer J. A one year study of trivalent influenza vaccines in primed and unprimed volunteers: immunogenicity, clinical reactions and protection. J Hyg Camb. 92:1984;263-276.
32. Wesselius-de Casparis A., Masurel N., Kerrebijn K.F. Field trial with human and equine influenza vaccines in children: protection and antibody titers. Bull World Health Organ. 46:1972;151-157.
33. Davies J.R., Grilli A. Natural or vaccine induced antibody as predictor of immunity in the face of natural challenge with influenza viruses. Epidemiol Infect. 102:1989;325-333.
34. Hobson D., Curry R.L., Beare A.S., Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond). 70:1972;767-777.